1 / 19

Deutsches Herzzentrum, Technische Universität, Munich Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen

Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus-Eluting Stents.

edaline
Download Presentation

Deutsches Herzzentrum, Technische Universität, Munich Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus-Eluting Stents Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada, Klaus Tiroch, Christian Valina, Karl-Ludwig Laugwitz, Steffen Massberg, Adnan Kastrati Deutsches Herzzentrum, Technische Universität, Munich Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen 1. Medizinische Klinik, Klinikum rechts der Isar, Munich. GERMANY ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  2. Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus-Eluting Stents Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches ISAR-DESIRE 3 ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  3. Disclosure Statement of Financial Interest I, Robert A. Byrne DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  4. Background The optimal treatment of drug-eluting stent (DES) restenosis remains unknown Drug-eluting balloon therapy has the advantage of avoiding additional stent layers but its role in the treatment of DES restenosis is poorly defined ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  5. Study Objective To compare the anti-restenotic efficacy of: paclitaxel-eluting balloon (SeQuent Please) versus paclitaxel-eluting stent (TaxusLiberte) versus balloon angioplasty alone in patients with limus-DES restenosis ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  6. Study Organization 402 patients with DES-restenosis enrolled between August 2009 and October 2011 in 3 centers in Germany Design DESIGN: Prospective, randomized, active controlled, multicenter clinical trial INCLUSION CRITERIA: Stenosis > 50% in “limus”-eluting DES Symptoms/signs of ischemia EXCLUSION CRITERIA: Lesion in left main stem Acute STEMI Cardiogenic shock SPONSOR: DeutschesHerzzentrum Paclitaxel-eluting balloon (SeQuent) (N=137) Paclitaxel-eluting stent (Taxus) (N=131) Balloon angioplasty alone (N=134) Angiographic follow-up at 6-8 months in 84.1% (N=338) Clinical follow-up at 12 months in 97.5% (N=392) No significant differences across groups ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  7. Study Organization 402 patients with DES-restenosis enrolled between August 2009 and October 2011 in 3 centers in Germany Design PRIMARY ENDPOINT: Percent diameter stenosis at follow-up angiography TEST HYPOTHESES: PEB non-inferior to PES %DS 35%; Delta = 7% alpha = 0.05; Power = 80% 102 Patients/group PEB and PES superior to balloon angioplasty %DS 35% vs. 45% alpha = 0.025; Power 90% 101 Patients/group Paclitaxel-eluting balloon (SeQuent) (N=137) Paclitaxel-eluting stent (Taxus) (N=131) Balloon angioplasty alone (N=134) Angiographic follow-up at 6-8 months in 84.1% (N=338) Clinical follow-up at 12 months in 97.5% (N=392) No significant differences across groups ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  8. Baseline Characteristics Patients No significant differences across groups ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  9. Baseline Characteristics Lesions No significant differences across groups ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  10. Baseline Characteristics Procedures No significant differences across groups; *in-stent analysis ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  11. Baseline Characteristics Procedures *No significant differences across groups † p<0.001 ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  12. Results ISAR-DESIRE 3 ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  13. Primary Endpoint Diameter Stenosis at Follow-up Angiography 100 Paclitaxel-Eluting Balloon (PEB) Paclitaxel-Eluting Stent (PES) 80 Balloon Angioplasty (BA) PEB versus BA PES versus BA Psuperiority <0.001 60 PEB 38.0% Cumulative Frequency (%) 40 PES 37.4% BA 54.1% 20 PEB versus PES Pnon-inferiority =0.007 0 0 20 40 60 80 100 Diameter Stenosis at Follow-up Angiography (%) ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  14. Secondary Endpoint Binary Restenosis Target Lesion Revascularization PEB versus BA PES versus BA P <0.001 PEB versus BA PES versus BA P <0.001 % % P = .61 P = .09 PEB PEB PES PES BA BA ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  15. Secondary Endpoint Death/Myocardial Infarction 50 % PEB versus PES P =.35 PEB versus BA P =.36 PES versus BA P =.97 40 30 Balloon Angioplasty 6.8% 20 Paclitaxel-Eluting Stent 6.9% Paclitaxel-Eluting Balloon 4.4% 10 0 0 2 4 6 8 10 12 ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  16. Secondary Endpoint Target Lesion Thrombosis PEB vs PES P =.97 PEB vs BA P =.33 PES vs BA P =.31 PEB PES BA % ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  17. Conclusions In patients presenting with “limus”-DES restenosis, PEB therapy is non-inferior to repeat stenting with PES Both PEB and PES therapy are superior to balloon angioplasty alone ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  18. Conclusions By obviating the need for additional stent implantation treatment with a drug-eluting balloon should be the treatment of choice in patients presenting with “limus”-DES restenosis ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

  19. Thank You Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis: 3 Treatment Approaches

More Related